These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 31378984)

  • 21. Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
    Li Y; Amaladas N; O'Mahony M; Manro JR; Inigo I; Li Q; Rasmussen ER; Brahmachary M; Doman TN; Hall G; Kalos M; Novosiadly R; Puig O; Pytowski B; Schaer DA
    PLoS One; 2022; 17(7):e0268244. PubMed ID: 35849586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
    Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
    Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
    Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
    Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X
    Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
    Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
    Front Immunol; 2021; 12():712351. PubMed ID: 34504494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8
    Liu Y; Zhang T; Zhang L; Zhao C; Zhang Z; Wang Z; Gu M; Li W; Li B
    Immunotherapy; 2022 Jun; 14(9):695-708. PubMed ID: 35574588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
    Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
    JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8
    Shan CK; Du YB; Zhai XT; Wang YX; Li Y; Gong JH; Ge ZJ; Liu XJ; Zhen YS
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):425-436. PubMed ID: 33388950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apatinib potentiates the therapeutic effect of anti-PD-1 in locally advanced head and neck cancers.
    Liu S; Zhang L; Ye W; Zhou R; Gu Z; Shi C; Xu S; Li J; Zhang Z; Han Y
    Oral Dis; 2024 Jul; 30(5):2940-2951. PubMed ID: 37846172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy.
    Li W; Zhan M; Quan YY; Wang H; Hua SN; Li Y; Zhang J; Lu L; Cui M
    Int Immunopharmacol; 2020 Apr; 81():106227. PubMed ID: 32078941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
    Sasaki T; Shigeta K; Kitahara S; Suzuki Y; Matsui S; Seishima R; Okabayashi K; Duda DG; Kitagawa Y
    Anticancer Res; 2022 Nov; 42(11):5205-5215. PubMed ID: 36288859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.